Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

NCT ID: NCT06642987

Last Updated: 2024-10-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-23
• Study Completion Date: 2024-02-23

Brief Summary

This clinical trial is an open-label, randomized, fasting, single-dose, two-sequence, two-period, crossover study in healthy subjects to evaluate the bioequivalence of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim Pharm.l Co., Ltd. and "Vocinti Tablet 20 mg (Vonoprazan Fumarate)" of Takeda Pharmaceuticals Korea Co., Ltd. in Healthy Adult Subjects.

Detailed Description

This study is to compare and evaluate the safety and pharmacokinetic characteristics of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim Pharm. Co., Ltd. as the test drug and "Vocinti Tablet 20 mg (Vonoprazan Fumarate)" of Takeda Pharmaceuticals Korea Co., Ltd. as the reference drug in healthy adults.

Conditions

Gastric Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Vonoprazan Test 20mg

On the day of the visit, take 1 tablet of the experimental drug orally with 150 mL of water around 8 am.

Group Type: EXPERIMENTAL

Vonoprazan Test 20mg

Intervention Type: DRUG

1 tablets orally once a day

Vonoprazan Reference 20mg

On the day of the visit, take 1 tablet of the comparator drug orally with 150 mL of water around 8 am.

Group Type: ACTIVE_COMPARATOR

Vonoprazan Reference 20mg

Intervention Type: DRUG

1 tablets orally once a day

Interventions

Vonoprazan Test 20mg

1 tablets orally once a day

Intervention Type: DRUG

Vonoprazan Reference 20mg

1 tablets orally once a day

Intervention Type: DRUG

Other Intervention Names

vonoprazan fumarate; Vonoprazna fumarate

Eligibility Criteria

Inclusion Criteria

1. Individuals aged 19 years or older at the time of screening

2. Individuals with no clinically significant congenital or chronic diseases and no pathological symptoms or findings based on medical examinations (such as EEG, ECG, chest and gastric endoscopy, or gastrointestinal radiology tests, if necessary)

3. Individuals deemed suitable for the study based on screening tests (e.g., hematology, blood chemistry, serology, and urinalysis) as determined by the principal investigator (or a designated sub-investigator)

4. Individuals with a Body Mass Index (BMI) between 18.0 and 30.0 (BMI calculation: weight (kg) / height (m)²)

5. Individuals with no history of gastrointestinal surgery that could affect drug absorption.

6. Individuals who, after receiving a detailed explanation of the clinical trial, fully understand the study, voluntarily decide to participate, and agree in writing to comply with the trial requirements during the study period.

Exclusion Criteria

1. Individuals who have taken enzyme-inducing or inhibiting drugs such as barbiturates within 30 days before the start of the study (first dosing day) or medications that might interfere with the study within 10 days before the start of the study (first dosing day)

2. Individuals who have engaged in excessive alcohol consumption within one month before the start of the study (first dosing day)

• For men, more than an average of 21 drinks per week
• For women, more than an average of 14 drinks per week (One drink: 45 mL of distilled spirits or 360 mL of beer or 150 mL of wine)

3. Individuals who have taken any medication that may interfere with the trial within 10 days prior to the start of the trial (first dose).

4. Individuals who have participated in clinical trials (including bioequivalence studies) and received investigational drugs within six months before the start of the study (first dosing day)

5. Individuals who have donated whole blood within 8 weeks or donated blood components within 2 weeks before the start of the study (first dosing day)

6. Patients with the following conditions:

• Hypersensitivity to the components of this drug
• Currently taking medications containing atazanavir, nelfinavir, or rilpivirine.

7. Individuals with a history of mental illness

8. Women who may be pregnant, pregnant women, or brestfeeding women

9. Individuals who do not agree to use medically recognized dual contraception* methods, excluding hormonal contraceptives, to prevent pregnancy from the first administration of the investigational drug until one week after the last administration of the investigational drug.

• Medically recognized dual contraception methods: Combining intrauterine devices (IUD, IUS), vasectomy, tubal ligation, and barrier methods of contraception (male condom, female condom, cervical cap, diaphragm, sponge, etc.), or using two or more barrier methods in combination with spermicides.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hanlim Pharm. Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Seok Gyeong Medical Foundation Central Hospital

Siheung-si, , South Korea

Countries

South Korea

Other Identifiers

DDS23-018BE

Identifier Type: -

Identifier Source: org_study_id